Cadrenal Therapeutics (CVKD) Total Liabilities (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Total Liabilities of $1.1 million for Q1 2026, down 32.94% sequentially from $1.6 million in Q4 2025, and down 42.13% YoY from $1.8 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Total Liabilities (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Total Liabilities for 5 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Total Liabilities fell 42.13% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 42.13% YoY) and the FY2025 annual result came in at $1.6 million, down 40.83% from the prior year.
- Total Liabilities fell to $1.1 million in Q1 2026 per CVKD's latest filing, from $1.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $6.3 million in Q4 2022 and troughed at $383104.0 in Q2 2023.
- A 5-year average of $1.6 million and a median of $1.3 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities tumbled 86.94% in 2023, then soared 282.38% in 2024.
- Over 5 years, Total Liabilities stood at $6.3 million in 2022, then sank by 86.94% to $826875.0 in 2023, then soared by 224.59% to $2.7 million in 2024, then plunged by 40.83% to $1.6 million in 2025, then tumbled by 32.94% to $1.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.1 million, $1.6 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 10.03 Bn |
| 10 | Cadrenal Therapeutics | 4.66 Mn | 2.26 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 856,315.00 |
| Dec 31, 2023 | 826,875.00 |
| Sep 30, 2023 | 565,798.00 |
| Jun 30, 2023 | 383,104.00 |
| Mar 31, 2023 | 416,802.00 |
| Dec 31, 2022 | 6.33 Mn |